中枢神经系统药物市场按药物类别、剂型、患者类型、作用机制、治疗领域、通路、製剂类型和销售模式划分－2025-2032 年全球预测

预计到 2032 年，中枢神经系统药物市场将成长至 494.6 亿美元，复合年增长率为 10.38%。

主要市场统计数据
基准年2024年	224.4亿美元
预计2025年	248亿美元
预测年份：2032年	494.6亿美元
复合年增长率（%）	10.38%

简述不断发展的中枢神经系统治疗格局，重点在于临床创新、病患需求和商业化驱动因素

由于科学进步的不断融合、监管预期的不断变化以及医疗服务模式的不断变化，中枢神经系统治疗领域正处于关键的十字路口。本执行摘要说明定义现代中枢神经系统治疗开发和商业化的广泛治疗层级、剂型、患者群体、作用机制和通路。透过阐明这些要素如何相互作用，读者可以更好地理解临床创新如何满足未满足的需求，以及哪些营运或政策限制需要主动缓解。

从止痛药和抗忧郁症到抗癫痫药和抗精神病药，开发策略越来越重视精准性、耐受性和长期安全性。新的製剂和给药技术旨在提高依从性并减少全身副作用，而数位医疗辅助工具则将自身定位为症状追踪和行为干预的补充解决方案。同时，付款人的期望和真实世界证据要求提高了证明相对有效性和价值的标准，从而影响了临床开发计划和商业化时间表。

中枢神经系统领域需要涵盖科学机制、病患细分和渠道动态的综合观点。本介绍将为深入分析重塑该领域的结构性变化、改变成本和供应考虑的政策变化，以及为目标产品和市场策略提供参考的细分洞察奠定基础。

神经科学、给药技术和护理模式的进步如何重塑中枢神经系统药物的开发、获取和生命週期策略

中枢神经系统领域的变革性转变是由科学、技术和医疗保健体系的融合趋势所驱动的。分子神经科学的进步以及对突触和神经传导物质路径理解的不断加深，正在催生新的治疗靶点，推动新类别的在临床实验药物的研发和现有疗法机制的改进。精准医疗方法植根于生物标记开发和分层试验设计，使得针对不同疾病状态的干预措施更具针对性，并由此重塑临床开发策略和监管参与。

与科学创新同步，给药科学和製剂工程正在改变患者的用药途径。缓释性平台、新型经皮系统和缓释肠外剂型正成为优先发展方向，以提高患者依从性，并在竞争激烈的治疗类别中实现产品差异化。数位化疗法和依从性工具正日益融入药物研发项目，以展示以患者为中心的疗效并支持报销谈判。这些互补工具也为超越生命週期管理和传统药品销售的全新收益模式创造了机会。

不断发展的医疗保健体係正在重新定义商业化管道。不断扩展的远距医疗、远端监控和基于药房的药物递送模式正在改变患者获取中枢神经系统药物的方式以及临床医生管理长期疾病的方式。同时，法律规范和付款方对真实世界证据的要求促使製造商在研发早期就规划核准后的证据产生。这些转变的共同作用正在创造一种新格局：科学新颖性、交付创新和证据生成必须协调一致，才能实现商业性和临床的成功。

了解美国关税变化对中枢神经系统治疗供应链弹性、製造选择和通路经济的多方面影响

近期源自美国的关税政策正在对中枢神经系统治疗药物的供应链、製造经济效益和战略采购决策施加多方面压力。依赖海外供应商原料药、辅料和成品的公司必须重新评估其供应商组合，并提高对分层供应关係的可视性，以维持供应的连续性。此类调整通常会提升地理多元化和双重采购安排的重要性，以吸收政策带来的成本和物流衝击。

关税主导的成本上涨将对中枢神经系统价值链的不同环节产生不同的影响。虽然提供差异化疗法的创新公司可能更有能力协商价格调整或透过价值争议吸收边际成本上涨，但低利润类别的学名药製造商将面临优化生产效率和确保低成本原材料的压力。考虑将某些製造活动转移到国内或扩大区域产能已成为产品组合规划讨论的常规内容，尤其对于需要復杂製造能力的剂型，例如缓释性口服固体製剂和特种注射剂。

为了因应与关税相关的干扰，商业团队也正在审视其分销策略。通路经济的变化可能会影响医院药房、零售药房网路和线上药房伙伴关係之间的平衡决策。此外，监管和付款方格局可能会透过影响报销动态和采购政策，进一步加剧关税的影响。这将更重视情境规划、明确与供应商的合约保护以及加强供应链管治，以保障医疗保健的连续性和商业性可行性。

基于药品类别、剂型、患者群、机制、治疗领域、通路、处方状态和销售模式的细分，提供深入洞察，实现精准的策略调整

详细的细分视图揭示了跨产品、患者、机制、治疗领域、通路、处方状态和销售模式维度的差异化商业机会和营运重点。依药品类别，有镇痛药、抗忧郁症、抗癫痫药、抗精神病药、抗焦虑药、中枢神经系统兴奋剂和镇静安眠药等类别。镇痛药类别进一步分为非阿片类镇痛药和阿片类镇痛药，每种镇痛药都有不同的临床考虑和监管审查。抗癫痫药物依作用机转分为钙通道阻断剂、GABA 增效剂、麸胺酸抑制剂和钠通道阻断剂，有助于临床前建模和临床终点选择。抗精神病药物分为非典型和典型，抗焦虑药物分为苯二氮平类和非苯二氮平类。兴奋剂的特征是安非他命和哌甲酯变体，而镇静催眠药则包括巴比妥类药物、苯二氮平类药物和非苯二氮平类催眠药。了解这些类别的差异对于临床定位和监管风险评估至关重要。

剂型类别包括胶囊、注射、口服锭、锭剂和经皮贴片。胶囊可以是标准缓释性，而注射剂可以是肌肉注射、静脉注射或皮下注射，每种途径都有各自的临床用例和供应链影响。口服製剂通常以混悬液或糖浆的形式提供，而药片则配製成延迟释放、缓释型或标准即时释型。经皮吸收贴片被设计为基质或储存系统，是提高某些适应症的依从性和稳态暴露的重要途径。这些剂量特性会影响开发的复杂性、监管提交、製造投资和商业性讯息。

病患类型细分可识别成人、老年和儿童病患群体，强调适合年龄的配方、给药策略和安全监测的必要性。作用机制细分突出了胆碱能、多巴胺能、GABA 能、麸胺酸、去甲肾上腺素能和血清素能方法，为生物标记选择和治疗方法差异化提供了框架。治疗领域细分包括注意力不足过动症 (ADHD)、阿兹海默症、焦虑、忧郁症、癫痫、失眠、偏头痛、疼痛、帕金森氏症和思觉失调症。每个领域都有不同的终点、合併症概况和相关人员的期望，这些都会影响临床开发和上市路径。分销通路细分（医院、线上和零售）会影响履约策略、病患援助计画和报销安排。处方药类型细分区分非处方药 (OTC) 和处方药，从而影响监管分类和消费者行销。销售模式细分区分品牌学名药，并决定促销力度、定价弹性和生命週期延长策略。这些细分共同构成一个矩阵，帮助决策者根据病患和市场需求调整研发重点、製造投资和商业性策略。

亚太地区、欧洲、中东和非洲的区域策略各不相同，确定监管策略、製造地和市场进入路线

区域动态对临床重点、监管参与、生产策略和商业性执行有重大影响。美洲市场环境受付款人主导的结果预期、成熟的临床试验生态系统以及有利于证明真实世界有效性的复杂报销结构的影响。临床开发往往强调比较疗效终点和长期安全性数据，而商业策略通常侧重于管理式医疗谈判以确保处方药覆盖、与专业药房合作以及与医生网络互动。

欧洲、中东和非洲的监管多样性和各自不同的采购体系，导致准入考量呈现错综复杂的局面。这一广大区域内的国家实施不同程度的集中评估和分散采购，要求製造商提供差异化的市场进入文件，以适应各国的医疗技术评估 (HTA) 流程和本地价格谈判。此外，与区域製造地和製造外包建立策略伙伴关係关係有助于管理市场准入和跨境供应链风险。临床开发计划通常会在早期纳入跨司法管辖区的要求，以简化核准和报销流程。

亚太地区临床试验活动强劲成长，生物製造投资不断增加，数位医疗应用日益普及。当地监管机构正在加强能力建设，简化创新疗法的批准流程，各国政府也正在投资建设关键疗法的国内生产能力。分销通路创新，尤其是线上药局模式和远端医疗服务的快速扩张，正在塑造慢性中枢神经系统疾病的可近性。这些区域特征要求我们根据当地支付者、处方者和患者的行为，客製化製造地决策、监管参与顺序和商业模式。

创新者、专业生物技术公司、学名药和製造合作伙伴为在中枢神经系统治疗领域获得竞争优势而采用的策略策略和协作方法

主要企业展现出多样化的策略态势，反映了其产品线成熟度、商业组合组成和营运优势。创新者强调差异化的作用机制和新颖的给药平台，以建立临床差异化，同时投资真实世界证据计画和病患支持服务，以验证其价值提案。特种生技公司通常专注于狭窄的适应症，且有大量未满足的需求，并可能寻求合作和许可，以加速后期开发和商业化。

学名药和契约製造正专注于规模化、成本优化和灵活的生产能力，以满足对成熟製剂类型的需求，并支援快速填充和完成生产。这些公司也正在探索复杂缓释性和经皮系统的生产机会，以赢得更高价值的生产合约。在治疗学和技术创新的交汇点，数位健康公司和平台提供者正在与製药公司合作，将依从性追踪、远端监控和疗效评估整合到产品价值链中，从而促进支持报销对话的新证据生成途径。

无论产品类型如何，有效的策略包括与学术中心和临床网络进行有针对性的合作，以接触特定患者群体；与监管机构及早沟通，明确证据预期；以及进行严格的生命週期管理，透过配方改进和产品说明书扩展来提升产品相关性。将研发重点与切合实际的商业性执行计划和强大的供应链管治相结合的公司，将最有能力应对中枢神经系统市场的复杂局面。

领导者应采取切实的策略措施，加强供应链韧性，使製剂创新与付款人证据保持一致，并加速中枢神经系统疗法的上市

产业领导者应制定一系列切实可行的优先事项，在科学抱负与营运及市场现实之间取得平衡。首先，透过多元化供应商关係，并采用关键活性成分和复杂辅料的双重采购，增强供应链的韧性。基于情境的采购计画和合约保护措施可以减轻政策中断的影响，并降低病患服务中断的风险。

其次，策略性地投资于符合依从性和安全性要求的剂型创新。缓释性、经皮系统和患者友善口服溶液可以使产品在竞争类别中脱颖而出，并支持改善临床疗效。产品团队必须将这些製剂选择与付款人证据需求以及可控制复杂性和上市时间的现实生产路径结合。

第三，从一开始就设计整合真实世界证据产生的开发项目。及早规划实用性试验、基于註册库的结果收集以及核准后安全性研究，可以加速报销讨论并强化临床价值主张。第四，优先制定有打入市场策略，透过及早与付款人和卫生技术评估机构沟通，了解证据阈值，并共同设计对覆盖决策至关重要的结果指标。

第五，我们将寻求与整个生态系统的伙伴关係——包括学术中心、数位医疗公司和经验丰富的合约研究机构——合作，以填补能力缺口并加快产品上市速度。最后，我们将实施差异化的商业策略，根据患者细分和医疗服务提供者的工作流程客製化通讯和管道组合，在适当情况下利用专业药房的能力，并采用线上药局管道来满足不断变化的患者偏好。

结合主要专家访谈、系统性二次综合和情境主导分析的调查方法概述，确保对中枢神经系统市场提供可重复且可操作的见解

本分析背后的调查方法将结构化的一手资料研究与全面的二次综合相结合，从而得出稳健的三角关联洞察。一手资料研究包括对参与中枢神经系统药物研发和分销的临床专家、监管专家、供应链经理以及商业领袖的深入访谈。这些访谈提供了关于临床重点、证据预期和运营限制的定性背景信息，为战略决策提供参考。

我们的二次研究包括对同行评审文献、临床试验註册库、监管指南、上市公司资讯揭露和行业会议资料的系统性回顾。数据在多个公共和资讯来源资讯来源之间进行交叉检验，以减少偏差并确保解读的一致性。我们也整合了近期产品上市和监管互动的案例分析，以揭示跨治疗层级和剂型的实用经验。

分析方法包括主题综合以识别跨领域趋势，情境规划以探索政策和供应链变化的影响，以及差距分析以发现未满足的临床和商业性需求。品管包括专家同行评审和透过迭代检验解决分歧。调查方法强调透明度、可重复性和可操作性的解读，确保研究结果可直接应用于投资组合规划、实质审查和打入市场策略。

整合以综合临床差异化、营运弹性和付款人一致证据生成为重点的策略要务，以确保持续的中枢神经系统市场准入

当从科学进步、製剂创新、监管演变和分销转型中获得的洞见相结合时，一个核心主题浮现：在中枢神经系统（CNS）治疗领域取得成功，需要整合策略。能够将机制新颖性转化为患者相关疗效，同时确保供应连续性和付款人一致性的公司将创造永续的价值。相反，低估现代付款人和医疗保健提供者的营运和证据生成需求的公司，儘管临床前景光明，但仍可能面临准入障碍。

清晰的策略规划植根于细分市场主导的规划、区域差异以及对供应链和政策动态的深入理解，使相关人员能够优先考虑投资并设计伙伴关係加速临床和商业里程碑的实现。本摘要中的建议旨在指南周到的行动，以加强供应链、提高依从性、选择差异化产品的配方和交付模式、儘早与付款人和监管机构沟通，并将真实世界证据纳入商业化计划。采用这些实践将有助于团队应对中枢神经系统 (CNS) 市场的复杂性，并定位新型和成熟疗法，以实现持续的临床和商业性影响力。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

• 采用人工智慧整合数位疗法进行个人化忧郁症管理的人数正在增加
• FDA核准新型神经保护药物，减缓阿兹海默症进展
• 扩大以迷幻药为基础的难治性精神疾病治疗方法新药研发管线
• 增加对精准医疗生物标记的投资，以预测癫痫治疗的有效性
• 用于思觉失调症抗精神病药物传递的长效植入装置的出现
• 加强生物技术与学术界的合作，加速中枢神经系统药物的发现与开发
• 整合真实世界数据和穿戴式装置以监测多发性硬化症的治疗结果

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 中枢神经系统药物市场（依药物类别）

• 止痛药
  • 非鸦片类止痛药
  • 阿片类止痛药
• 抗忧郁症
• 抗癫痫药物
  • 钙离子通道阻断剂
  • GABA增强剂
  • 麸胺酸抑制剂
  • 钠通道阻断剂
• 抗精神病药物
  • 非典型
  • 固定形式
• 抗焦虑药物
  • 苯二氮平类药物
  • 非苯二氮平类药物
• 中枢神经兴奋剂
  • 安非他命
  • 哌甲酯
• 催眠镇静剂
  • 巴比妥类药物
  • 苯二氮平类药物
  • 非苯二氮平类催眠药

9. 中枢神经系统药物市场（按剂型）

• 胶囊
  • 缓释性胶囊
  • 标准胶囊
• 注射液
  • IM
  • IV
  • 皮下
• 口服溶液
  • 暂停
  • 糖浆
• 药片
  • 延迟释放片
  • 缓释片
  • 标准平板电脑
• 经皮吸收贴片
  • 矩阵补丁
  • 水库斑块

第 10 章：中枢神经系统药物市场（依病患类型）

• 成人
• 老年人
• 孩子们

第 11 章：中枢神经系统药物市场（依作用机转）

• 胆碱能
• 多巴胺能
• GABA能
• 麸胺酸
• 去甲肾上腺素能
• 血清素能

12. 中枢神经系统药物市场（依治疗领域）

• ADHD
• 阿兹海默症
• 焦虑
• 忧郁症
• 癫痫
• 失眠
• 偏头痛
• 疼痛
• 帕金森氏症
• 思觉失调症

13. 中枢神经系统药物市场（依分销管道）

• 医院药房
• 网路药局
• 零售药局

第 14 章中枢神经系统药物市场（按剂型）

• OTC
• 处方笺

第 15 章中枢神经系统药物市场（依销售模式）

• 品牌
• 非专利的

16. 中枢神经系统药物市场（按地区）

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第 17 章：中枢神经系统药物市场（依类别）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第 18 章：各国中枢神经系统药物市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十九章 竞争态势

• 2024年市占率分析
• 2024年FPNV定位矩阵
• 竞争分析
  • Roche Holding AG
  • Biogen Inc.
  • Novartis AG
  • Johnson & Johnson
  • Otsuka Pharmaceutical Co., Ltd.
  • Eli Lilly and Company
  • Teva Pharmaceutical Industries Ltd.
  • H. Lundbeck A/S
  • Pfizer Inc.
  • Sanofi SA

The Central Nervous System Drugs Market is projected to grow by USD 49.46 billion at a CAGR of 10.38% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 22.44 billion
Estimated Year [2025]	USD 24.80 billion
Forecast Year [2032]	USD 49.46 billion
CAGR (%)	10.38%

A concise orientation to the evolving central nervous system therapeutics landscape emphasizing clinical innovation, patient needs, and commercialization drivers

The central nervous system therapeutics domain is at a pivotal juncture, shaped by converging scientific advances, evolving regulatory expectations, and shifting patterns of care delivery. This executive summary provides a focused orientation to the broad set of therapeutic classes, dosage formats, patient populations, mechanisms of action, and distribution pathways that define contemporary CNS drug development and commercialization. By clarifying how these elements interact, readers can better understand where clinical innovation aligns with unmet needs, and where operational or policy-driven constraints require proactive mitigation.

Across the spectrum from analgesics and antidepressants to antiepileptics and antipsychotics, development strategies increasingly prioritize precision, tolerability, and long-term safety. New formulations and delivery technologies seek to improve adherence and reduce systemic adverse effects, while digital health adjuncts are positioning themselves as complementary solutions for symptom tracking and behavioral interventions. Concurrently, payer expectations and real-world evidence requirements are raising the bar for demonstrating comparative effectiveness and value, influencing both clinical development plans and commercialization timelines.

The central nervous system area demands an integrated view that spans scientific mechanism, patient segmentation, and channel dynamics. This introduction sets the stage for a deeper analysis of the structural shifts reshaping the landscape, the policy changes that are altering cost and supply considerations, and the segmentation insights that inform targeted product and market strategies.

How converging advances in neuroscience, delivery technologies, and care models are reshaping development, access, and lifecycle strategies in CNS therapeutics

Transformative shifts in the central nervous system field are being driven by convergent trends across science, technology, and health systems. Advances in molecular neuroscience and an improved understanding of synaptic and neurotransmitter pathways have created novel targets for modulation, prompting new classes of investigational agents and mechanistic refinements of existing therapies. Precision approaches-rooted in biomarker development and stratified trial designs-are enabling more targeted interventions for heterogeneous conditions, and this, in turn, is reshaping clinical development strategies and regulatory engagement.

Parallel to scientific innovation, delivery science and formulation engineering are altering routes to patient access. Extended-release platforms, novel transdermal systems, and parenteral formats designed for sustained delivery are being prioritized to improve adherence and to differentiate products in crowded therapeutic categories. Digital therapeutics and connected adherence tools are increasingly integrated with drug development programs to demonstrate patient-centric outcomes and to support reimbursement discussions. These adjuncts also create opportunities for lifecycle management and new revenue models that extend beyond traditional pharmaceutical sales.

Health system evolution is redefining commercialization channels. Telemedicine expansion, remote monitoring, and pharmacy delivery models are changing how patients obtain CNS therapies and how clinicians manage long-term conditions. At the same time, regulatory frameworks and payer expectations for real-world evidence are encouraging manufacturers to plan post-authorization evidence generation earlier in development. The combined effect of these shifts is a landscape in which scientific novelty, delivery innovation, and evidence generation must be orchestrated to succeed commercially and clinically.

Understanding the multifaceted influence of evolving U.S. tariffs on supply chain resilience, manufacturing choices, and channel economics for CNS therapeutics

Recent tariff policies originating from the United States have exerted multi-dimensional pressure on CNS drug supply chains, manufacturing economics, and strategic sourcing decisions. Companies that rely on international suppliers for active pharmaceutical ingredients, excipients, or finished dosage forms have needed to reassess vendor portfolios and to increase visibility into tiered supply relationships to maintain continuity of supply. This recalibration often elevates the importance of geographic diversification and of dual sourcing arrangements that can absorb policy-induced cost and logistical shocks.

Tariff-driven cost increases affect different segments of the CNS value chain in distinct ways. Innovator companies with differentiated therapeutic offerings may be better positioned to negotiate price adjustments or to absorb marginal cost increases through value arguments, whereas generic manufacturers operating in thin-margin categories face heightened pressure to optimize production efficiency and to secure low-cost raw materials. Deliberations around onshoring certain manufacturing activities or expanding regional production capacity are now routine elements of portfolio planning conversations, especially for dosage forms that demand complex manufacturing capabilities such as extended-release oral solids or specialized injectable solutions.

In response to tariff-related disruptions, commercial teams have also scrutinized distribution strategies. Shifts in channel economics can influence decisions about the balance between hospital pharmacies, retail pharmacy networks, and online pharmacy partnerships. Moreover, regulatory and payer landscapes can compound tariff effects by influencing reimbursement dynamics and procurement sourcing policies. The net result is a heightened emphasis on scenario planning, clearer contractual protections with suppliers, and more robust supply chain governance to protect both continuity of care and commercial viability.

Deep segmentation-driven insights across drug class, formulation, patient cohort, mechanism, therapeutic area, channel, prescription status, and sales model for precise strategic alignment

A granular view of segmentation reveals differentiated opportunities and operational priorities across product, patient, mechanism, therapeutic area, channel, prescription status, and sales model dimensions. Within drug classes, the market spans analgesic, antidepressant, antiepileptic, antipsychotic, anxiolytic, CNS stimulant, and hypnotic and sedative categories. The analgesic category further divides into non-opioid and opioid analgesics, each with distinct clinical considerations and regulatory scrutiny. Antiepileptic agents cluster by mechanism into calcium channel blockers, GABA enhancers, glutamate inhibitors, and sodium channel blockers, which informs both preclinical modeling and clinical endpoint selection. Antipsychotic compounds bifurcate into atypical and typical classes, while anxiolytics are differentiated into benzodiazepine and non-benzodiazepine treatments. CNS stimulants are characterized by amphetamines and methylphenidate variants, and hypnotic and sedative modalities include barbiturates, benzodiazepines, and non-benzodiazepine hypnotics. Understanding these class-level distinctions is critical for clinical positioning and regulatory risk assessment.

Dosage form segmentation spans capsule, injectable solution, oral solution, tablet, and transdermal patch presentations. Capsules may be standard or extended-release, and injectable solutions may be administered intramuscularly, intravenously, or subcutaneously, each route carrying unique clinical use cases and supply chain implications. Oral solutions are typically provided as suspensions or syrups, whereas tablets can be formulated as delayed-release, extended-release, or standard immediate-release types. Transdermal patches are engineered as matrix or reservoir systems, and they represent an important route for improving adherence and steady-state exposure in select indications. These dosage characteristics influence development complexity, regulatory dossiers, manufacturing investments, and commercial messaging.

Patient type segmentation identifies adult, geriatric, and pediatric populations, underscoring the need for age-appropriate formulations, dosing strategies, and safety monitoring. Mechanism of action segmentation highlights cholinergic, dopaminergic, GABAergic, glutamatergic, noradrenergic, and serotonergic approaches, providing a framework for biomarker selection and for therapeutic differentiation. Therapeutic area segmentation includes ADHD, Alzheimer's disease, anxiety, depression, epilepsy, insomnia, migraine, pain, Parkinson's disease, and schizophrenia; each area brings distinct endpoints, comorbidity profiles, and stakeholder expectations that shape both clinical development and market access pathways. Distribution channel segmentation-hospital pharmacy, online pharmacy, and retail pharmacy-affects fulfillment strategies, patient support programs, and reimbursement alignment. Prescription type segmentation differentiates over-the-counter from prescription products, which has implications for regulatory classification and consumer marketing. Sales model segmentation separates branded from generic offerings, determining the intensity of promotional activity, pricing flexibility, and lifecycle extension tactics. Together, these segmentation lenses create a matrix that decision-makers can use to align R&D priorities, manufacturing investments, and commercial tactics with distinct patient and market needs.

Regional strategic differences across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine regulatory strategy, manufacturing location, and market access pathways

Regional dynamics materially influence clinical priorities, regulatory engagement, manufacturing strategy, and commercial execution. In the Americas, the market environment is shaped by payer-driven outcomes expectations, a mature clinical trial ecosystem, and a complex reimbursement architecture that privileges demonstrable real-world effectiveness. Clinical development tends to emphasize comparative effectiveness endpoints and long-term safety data, while commercial strategies often concentrate on managed care negotiations, specialty pharmacy partnerships, and physician network engagement to secure formulary placement.

In Europe, Middle East & Africa, regulatory diversity and heterogeneous procurement systems create a mosaic of access considerations. Countries within this wider region exhibit varying degrees of centralized assessment versus decentralized procurement, and manufacturers need differentiated market access dossiers to address national HTA processes and local pricing negotiations. In addition, regional manufacturing hubs and strategic partnerships with contract manufacturers can be instrumental for market entry and for managing cross-border supply chain risks. Clinical development plans often incorporate multi-jurisdictional requirements early to streamline approvals and reimbursement discussions.

In Asia-Pacific, strong growth in clinical trial activity, rising investment in biomanufacturing, and increasing digital health adoption are notable. Local regulatory authorities are enhancing capabilities and streamlining pathways for innovative therapies, and governments are investing in domestic production capacity for critical therapeutics. Distribution channel innovation-especially rapid expansion of online pharmacy models and telehealth services-shapes access pathways for chronic CNS conditions. Together, these regional characteristics should inform manufacturing location decisions, regulatory engagement sequencing, and tailored commercial models that reflect payers, prescribers, and patient behavior in each geography.

Strategic playbooks and collaborative approaches adopted by innovators, specialty biotechs, generics, and manufacturing partners to gain competitive advantage in CNS therapies

Key companies operating in the central nervous system space demonstrate a range of strategic postures that reflect their pipeline maturity, commercial portfolio composition, and operational strengths. Innovator firms emphasize differentiated mechanisms of action and novel delivery platforms to establish clinical differentiation, while also investing in real-world evidence programs and patient support services to substantiate value propositions. Specialty biotechs often focus on narrow indications with high unmet need and may pursue partnerships or licensing to accelerate late-stage development and commercialization.

Generic and contract manufacturing organizations are concentrating on scale, cost optimization, and flexible manufacturing capabilities to meet demand for established formulation types and to support rapid fill-and-finish needs. These players also explore opportunities to manufacture complex modified-release products and transdermal systems as a route to capture higher-value manufacturing contracts. At the intersection of therapeutic and technology innovation, digital health companies and platform providers are collaborating with pharmaceutical firms to integrate adherence tracking, remote monitoring, and outcome measurement into product value chains, facilitating new evidence generation pathways that support reimbursement dialogues.

Across company types, effective strategies include targeted alliance formation with academic centers and clinical networks to access specialized patient populations, early engagement with regulatory authorities to clarify evidentiary expectations, and disciplined lifecycle management to extend product relevance through formulation improvements or label expansions. Firms that align R&D priorities with pragmatic commercial execution plans and robust supply chain governance are best positioned to navigate the complexity of CNS markets.

Practical strategic imperatives for leaders to bolster supply chain resilience, align formulation innovation with payer evidence, and accelerate market access in CNS therapeutics

Industry leaders should pursue a set of actionable priorities that balance scientific ambition with operational pragmatism and market realism. First, strengthen supply chain resilience by diversifying supplier relationships and incorporating dual sourcing for critical active ingredients and complex excipients. Scenario-based procurement planning and contractual protections can mitigate policy-driven disruptions and reduce the risk of service interruptions for patients.

Second, invest strategically in dosage form innovation that aligns with adherence and safety imperatives. Extended-release formulations, transdermal systems, and patient-friendly oral solutions can differentiate products in competitive categories and support improved clinical outcomes. Product teams should align these formulation choices with payer evidence needs and with pragmatic manufacturing pathways that control complexity and time to market.

Third, design development programs that integrate real-world evidence generation from the outset. Early planning for pragmatic trials, registry-based outcome collection, and post-authorization safety studies can accelerate reimbursement discussions and strengthen clinical value claims. Fourth, prioritize targeted market access strategies by engaging payers and health technology assessment bodies early to understand evidence thresholds and to co-design outcome measures that matter for coverage decisions.

Fifth, pursue partnerships across the ecosystem-including academic centers, digital health firms, and experienced contract development organizations-to fill capability gaps and to accelerate time-to-market. Finally, execute a differentiated commercial strategy that tailors messaging and channel mix to patient segments and provider workflows, leveraging specialty pharmacy capabilities where appropriate and embracing online pharmacy channels to meet evolving patient preferences.

Methodological overview combining primary expert interviews, systematic secondary synthesis, and scenario-driven analysis to ensure reproducible and actionable CNS market insights

The research methodology behind this analysis combines structured primary inquiry with comprehensive secondary synthesis to produce robust, triangulated insights. Primary research activities included in-depth interviews with clinical experts, regulatory specialists, supply chain managers, and commercial leaders involved in central nervous system drug development and distribution. These conversations provided qualitative context around clinical priorities, evidentiary expectations, and operational constraints that inform strategic decision-making.

Secondary research involved systematic review of peer-reviewed literature, clinical trial registries, regulatory guidance, public company disclosures, and industry conference materials. Data were cross-validated across multiple public and proprietary sources to reduce bias and to ensure consistency of interpretation. The study also integrated case-based analyses of recent product launches and regulatory interactions to surface practical lessons that are relevant across therapeutic classes and dosage forms.

Analytic techniques included thematic synthesis to identify cross-cutting trends, scenario planning to explore the implications of policy and supply chain shifts, and gap analysis to expose unmet clinical and commercial needs. Quality control measures included peer review by subject matter experts and reconciliation of divergent perspectives through iterative validation. The methodology emphasizes transparency, reproducibility, and pragmatic interpretation so that findings can be directly applied to portfolio planning, due diligence, and market entry strategy.

Synthesis of strategic imperatives emphasizing integrated clinical differentiation, operational resilience, and payer-aligned evidence generation to secure durable CNS market access

The combined insights from scientific advances, formulation innovation, regulatory evolution, and distribution transformation point to a central theme: success in the central nervous system therapeutics domain requires integrated strategy that aligns clinical differentiation with operational excellence. Companies that can translate mechanistic novelty into patient-relevant outcomes while ensuring supply continuity and payer alignment stand to create sustainable value. Conversely, firms that underestimate the operational or evidence-generation demands of contemporary payers and providers may face access barriers despite clinical promise.

Strategic clarity-rooted in segmentation-driven planning, regional nuance, and a rigorous appreciation of supply chain and policy dynamics-enables stakeholders to prioritize investments and to design partnerships that accelerate clinical and commercial milestones. The recommendations in this summary are intended to guide deliberative action: fortify supply networks, select formulation and delivery modalities that improve adherence and differentiate products, engage payers and regulators early, and integrate real-world evidence into commercialization plans. By adopting these practices, teams can better navigate the complexity of CNS markets and position novel and established therapies for durable clinical and commercial impact.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Rising adoption of digital therapeutics integrating AI for personalized depression management
• 5.2. Accelerated FDA approvals of novel neuroprotective agents for Alzheimer's disease progression
• 5.3. Expansion of pipeline of novel psychedelic-based treatments for treatment resistant psychiatric disorders
• 5.4. Increased investment in precision medicine biomarkers to predict efficacy of epilepsy therapies
• 5.5. Emergence of long acting implantable devices for sustained antipsychotic drug delivery in schizophrenia
• 5.6. Growing collaboration between biotech and academic institutions to accelerate CNS drug discovery and development
• 5.7. Integration of real world data and wearables for monitoring treatment outcomes in multiple sclerosis management

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Central Nervous System Drugs Market, by Drug Class

• 8.1. Analgesic
  • 8.1.1. Non-Opioid Analgesic
  • 8.1.2. Opioid Analgesic
• 8.2. Antidepressant
• 8.3. Antiepileptic
  • 8.3.1. Calcium Channel Blocker
  • 8.3.2. Gaba Enhancer
  • 8.3.3. Glutamate Inhibitor
  • 8.3.4. Sodium Channel Blocker
• 8.4. Antipsychotic
  • 8.4.1. Atypical
  • 8.4.2. Typical
• 8.5. Anxiolytic
  • 8.5.1. Benzodiazepine
  • 8.5.2. Non-Benzodiazepine
• 8.6. Cns Stimulant
  • 8.6.1. Amphetamines
  • 8.6.2. Methylphenidate
• 8.7. Hypnotic And Sedative
  • 8.7.1. Barbiturates
  • 8.7.2. Benzodiazepine
  • 8.7.3. Non-Benzodiazepine Hypnotics

9. Central Nervous System Drugs Market, by Dosage Form

• 9.1. Capsule
  • 9.1.1. Extended-Release Capsule
  • 9.1.2. Standard Capsule
• 9.2. Injectable Solution
  • 9.2.1. Im
  • 9.2.2. Iv
  • 9.2.3. Subcutaneous
• 9.3. Oral Solution
  • 9.3.1. Suspension
  • 9.3.2. Syrup
• 9.4. Tablet
  • 9.4.1. Delayed-Release Tablet
  • 9.4.2. Extended-Release Tablet
  • 9.4.3. Standard Tablet
• 9.5. Transdermal Patch
  • 9.5.1. Matrix Patch
  • 9.5.2. Reservoir Patch

10. Central Nervous System Drugs Market, by Patient Type

• 10.1. Adult
• 10.2. Geriatric
• 10.3. Pediatric

11. Central Nervous System Drugs Market, by Mechanism Of Action

• 11.1. Cholinergic
• 11.2. Dopaminergic
• 11.3. Gabaergic
• 11.4. Glutamatergic
• 11.5. Noradrenergic
• 11.6. Serotonergic

12. Central Nervous System Drugs Market, by Therapeutic Area

• 12.1. ADHD
• 12.2. Alzheimer's Disease
• 12.3. Anxiety
• 12.4. Depression
• 12.5. Epilepsy
• 12.6. Insomnia
• 12.7. Migraine
• 12.8. Pain
• 12.9. Parkinson's Disease
• 12.10. Schizophrenia

13. Central Nervous System Drugs Market, by Distribution Channel

• 13.1. Hospital Pharmacy
• 13.2. Online Pharmacy
• 13.3. Retail Pharmacy

14. Central Nervous System Drugs Market, by Prescription Type

• 14.1. Over The Counter
• 14.2. Prescription

15. Central Nervous System Drugs Market, by Sales Model

• 15.1. Branded
• 15.2. Generic

16. Central Nervous System Drugs Market, by Region

• 16.1. Americas
  • 16.1.1. North America
  • 16.1.2. Latin America
• 16.2. Europe, Middle East & Africa
  • 16.2.1. Europe
  • 16.2.2. Middle East
  • 16.2.3. Africa
• 16.3. Asia-Pacific

17. Central Nervous System Drugs Market, by Group

• 17.1. ASEAN
• 17.2. GCC
• 17.3. European Union
• 17.4. BRICS
• 17.5. G7
• 17.6. NATO

18. Central Nervous System Drugs Market, by Country

• 18.1. United States
• 18.2. Canada
• 18.3. Mexico
• 18.4. Brazil
• 18.5. United Kingdom
• 18.6. Germany
• 18.7. France
• 18.8. Russia
• 18.9. Italy
• 18.10. Spain
• 18.11. China
• 18.12. India
• 18.13. Japan
• 18.14. Australia
• 18.15. South Korea

19. Competitive Landscape

• 19.1. Market Share Analysis, 2024
• 19.2. FPNV Positioning Matrix, 2024
• 19.3. Competitive Analysis
  • 19.3.1. Roche Holding AG
  • 19.3.2. Biogen Inc.
  • 19.3.3. Novartis AG
  • 19.3.4. Johnson & Johnson
  • 19.3.5. Otsuka Pharmaceutical Co., Ltd.
  • 19.3.6. Eli Lilly and Company
  • 19.3.7. Teva Pharmaceutical Industries Ltd.
  • 19.3.8. H. Lundbeck A/S
  • 19.3.9. Pfizer Inc.
  • 19.3.10. Sanofi S.A.

LIST OF FIGURES

• FIGURE 1. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
• FIGURE 13. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2024 VS 2032 (%)
• FIGURE 15. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SALES MODEL, 2024 VS 2032 (%)
• FIGURE 17. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SALES MODEL, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. AMERICAS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. NORTH AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. LATIN AMERICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. EUROPE CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. MIDDLE EAST CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. AFRICA CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. ASEAN CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. GCC CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 30. EUROPEAN UNION CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 31. BRICS CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 32. G7 CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 33. NATO CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 34. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 35. CENTRAL NERVOUS SYSTEM DRUGS MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 36. CENTRAL NERVOUS SYSTEM DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. CENTRAL NERVOUS SYSTEM DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANALGESIC, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANALGESIC, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANALGESIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANALGESIC, BY REGION, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANALGESIC, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANALGESIC, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANALGESIC, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANALGESIC, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NON-OPIOID ANALGESIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NON-OPIOID ANALGESIC, BY REGION, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NON-OPIOID ANALGESIC, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NON-OPIOID ANALGESIC, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NON-OPIOID ANALGESIC, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NON-OPIOID ANALGESIC, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY OPIOID ANALGESIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY OPIOID ANALGESIC, BY REGION, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY OPIOID ANALGESIC, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY OPIOID ANALGESIC, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY OPIOID ANALGESIC, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY OPIOID ANALGESIC, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIDEPRESSANT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIDEPRESSANT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIDEPRESSANT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIDEPRESSANT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIDEPRESSANT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIDEPRESSANT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIEPILEPTIC, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIEPILEPTIC, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIEPILEPTIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIEPILEPTIC, BY REGION, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIEPILEPTIC, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIEPILEPTIC, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIEPILEPTIC, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIEPILEPTIC, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKER, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKER, BY REGION, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKER, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKER, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKER, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKER, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GABA ENHANCER, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GABA ENHANCER, BY REGION, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GABA ENHANCER, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GABA ENHANCER, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GABA ENHANCER, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GABA ENHANCER, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GLUTAMATE INHIBITOR, BY REGION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GLUTAMATE INHIBITOR, BY REGION, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GLUTAMATE INHIBITOR, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GLUTAMATE INHIBITOR, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GLUTAMATE INHIBITOR, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GLUTAMATE INHIBITOR, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SODIUM CHANNEL BLOCKER, BY REGION, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SODIUM CHANNEL BLOCKER, BY REGION, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SODIUM CHANNEL BLOCKER, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SODIUM CHANNEL BLOCKER, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SODIUM CHANNEL BLOCKER, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SODIUM CHANNEL BLOCKER, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIPSYCHOTIC, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIPSYCHOTIC, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIPSYCHOTIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIPSYCHOTIC, BY REGION, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIPSYCHOTIC, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIPSYCHOTIC, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIPSYCHOTIC, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANTIPSYCHOTIC, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ATYPICAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ATYPICAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ATYPICAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ATYPICAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ATYPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ATYPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TYPICAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TYPICAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TYPICAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TYPICAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TYPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TYPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANXIOLYTIC, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANXIOLYTIC, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANXIOLYTIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANXIOLYTIC, BY REGION, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANXIOLYTIC, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANXIOLYTIC, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANXIOLYTIC, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ANXIOLYTIC, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BENZODIAZEPINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BENZODIAZEPINE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BENZODIAZEPINE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BENZODIAZEPINE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BENZODIAZEPINE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BENZODIAZEPINE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NON-BENZODIAZEPINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NON-BENZODIAZEPINE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NON-BENZODIAZEPINE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NON-BENZODIAZEPINE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NON-BENZODIAZEPINE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NON-BENZODIAZEPINE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CNS STIMULANT, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CNS STIMULANT, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CNS STIMULANT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CNS STIMULANT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CNS STIMULANT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CNS STIMULANT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CNS STIMULANT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CNS STIMULANT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY AMPHETAMINES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY AMPHETAMINES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY AMPHETAMINES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY AMPHETAMINES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY AMPHETAMINES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY AMPHETAMINES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY METHYLPHENIDATE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY METHYLPHENIDATE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY METHYLPHENIDATE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY METHYLPHENIDATE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY METHYLPHENIDATE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY METHYLPHENIDATE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY HYPNOTIC AND SEDATIVE, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY HYPNOTIC AND SEDATIVE, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY HYPNOTIC AND SEDATIVE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY HYPNOTIC AND SEDATIVE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY HYPNOTIC AND SEDATIVE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY HYPNOTIC AND SEDATIVE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY HYPNOTIC AND SEDATIVE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY HYPNOTIC AND SEDATIVE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BARBITURATES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BARBITURATES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BARBITURATES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BARBITURATES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BARBITURATES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BARBITURATES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BENZODIAZEPINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BENZODIAZEPINE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BENZODIAZEPINE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BENZODIAZEPINE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BENZODIAZEPINE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY BENZODIAZEPINE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NON-BENZODIAZEPINE HYPNOTICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NON-BENZODIAZEPINE HYPNOTICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NON-BENZODIAZEPINE HYPNOTICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NON-BENZODIAZEPINE HYPNOTICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NON-BENZODIAZEPINE HYPNOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY NON-BENZODIAZEPINE HYPNOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
• TABLE 153. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CAPSULE, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CAPSULE, 2025-2032 (USD MILLION)
• TABLE 155. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 156. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 157. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 158. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 159. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 160. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 161. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY EXTENDED-RELEASE CAPSULE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 162. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY EXTENDED-RELEASE CAPSULE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 163. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY EXTENDED-RELEASE CAPSULE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 164. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY EXTENDED-RELEASE CAPSULE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 165. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY EXTENDED-RELEASE CAPSULE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 166. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY EXTENDED-RELEASE CAPSULE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 167. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY STANDARD CAPSULE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 168. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY STANDARD CAPSULE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 169. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY STANDARD CAPSULE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 170. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY STANDARD CAPSULE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 171. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY STANDARD CAPSULE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 172. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY STANDARD CAPSULE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 173. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY INJECTABLE SOLUTION, 2018-2024 (USD MILLION)
• TABLE 174. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY INJECTABLE SOLUTION, 2025-2032 (USD MILLION)
• TABLE 175. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY INJECTABLE SOLUTION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 176. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY INJECTABLE SOLUTION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 177. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY INJECTABLE SOLUTION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 178. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY INJECTABLE SOLUTION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 179. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY INJECTABLE SOLUTION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 180. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY INJECTABLE SOLUTION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 181. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY IM, BY REGION, 2018-2024 (USD MILLION)
• TABLE 182. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY IM, BY REGION, 2025-2032 (USD MILLION)
• TABLE 183. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY IM, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 184. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY IM, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 185. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY IM, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 186. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY IM, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 187. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY IV, BY REGION, 2018-2024 (USD MILLION)
• TABLE 188. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY IV, BY REGION, 2025-2032 (USD MILLION)
• TABLE 189. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY IV, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 190. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY IV, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 191. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY IV, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 192. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY IV, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 193. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 194. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 195. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 196. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 197. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 198. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 199. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ORAL SOLUTION, 2018-2024 (USD MILLION)
• TABLE 200. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ORAL SOLUTION, 2025-2032 (USD MILLION)
• TABLE 201. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ORAL SOLUTION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 202. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ORAL SOLUTION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 203. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ORAL SOLUTION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 204. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ORAL SOLUTION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 205. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ORAL SOLUTION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 206. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ORAL SOLUTION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 207. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 208. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SUSPENSION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 209. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SUSPENSION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 210. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SUSPENSION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 211. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SUSPENSION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 212. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SUSPENSION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 213. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SYRUP, BY REGION, 2018-2024 (USD MILLION)
• TABLE 214. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SYRUP, BY REGION, 2025-2032 (USD MILLION)
• TABLE 215. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SYRUP, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 216. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SYRUP, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 217. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SYRUP, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 218. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY SYRUP, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 219. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TABLET, 2018-2024 (USD MILLION)
• TABLE 220. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TABLET, 2025-2032 (USD MILLION)
• TABLE 221. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
• TABLE 222. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TABLET, BY REGION, 2025-2032 (USD MILLION)
• TABLE 223. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 224. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 225. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 226. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 227. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DELAYED-RELEASE TABLET, BY REGION, 2018-2024 (USD MILLION)
• TABLE 228. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DELAYED-RELEASE TABLET, BY REGION, 2025-2032 (USD MILLION)
• TABLE 229. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DELAYED-RELEASE TABLET, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 230. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DELAYED-RELEASE TABLET, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 231. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DELAYED-RELEASE TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 232. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DELAYED-RELEASE TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 233. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY EXTENDED-RELEASE TABLET, BY REGION, 2018-2024 (USD MILLION)
• TABLE 234. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY EXTENDED-RELEASE TABLET, BY REGION, 2025-2032 (USD MILLION)
• TABLE 235. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY EXTENDED-RELEASE TABLET, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 236. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY EXTENDED-RELEASE TABLET, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 237. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY EXTENDED-RELEASE TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 238. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY EXTENDED-RELEASE TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 239. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY STANDARD TABLET, BY REGION, 2018-2024 (USD MILLION)
• TABLE 240. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY STANDARD TABLET, BY REGION, 2025-2032 (USD MILLION)
• TABLE 241. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY STANDARD TABLET, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 242. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY STANDARD TABLET, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 243. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY STANDARD TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 244. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY STANDARD TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 245. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, 2018-2024 (USD MILLION)
• TABLE 246. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, 2025-2032 (USD MILLION)
• TABLE 247. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, BY REGION, 2018-2024 (USD MILLION)
• TABLE 248. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, BY REGION, 2025-2032 (USD MILLION)
• TABLE 249. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 250. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 251. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 252. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY TRANSDERMAL PATCH, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 253. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MATRIX PATCH, BY REGION, 2018-2024 (USD MILLION)
• TABLE 254. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MATRIX PATCH, BY REGION, 2025-2032 (USD MILLION)
• TABLE 255. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MATRIX PATCH, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 256. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MATRIX PATCH, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 257. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MATRIX PATCH, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 258. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MATRIX PATCH, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 259. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY RESERVOIR PATCH, BY REGION, 2018-2024 (USD MILLION)
• TABLE 260. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY RESERVOIR PATCH, BY REGION, 2025-2032 (USD MILLION)
• TABLE 261. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY RESERVOIR PATCH, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 262. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY RESERVOIR PATCH, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 263. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY RESERVOIR PATCH, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 264. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY RESERVOIR PATCH, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 265. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
• TABLE 266. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
• TABLE 267. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 268. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 269. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 270. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 271. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 272. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 273. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 274. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
• TABLE 275. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 276. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 277. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 278. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 279. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 280. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
• TABLE 281. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 282. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 283. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 284. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 285. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
• TABLE 286. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
• TABLE 287. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CHOLINERGIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 288. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CHOLINERGIC, BY REGION, 2025-2032 (USD MILLION)
• TABLE 289. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CHOLINERGIC, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 290. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CHOLINERGIC, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 291. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CHOLINERGIC, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 292. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY CHOLINERGIC, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 293. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DOPAMINERGIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 294. GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET SIZE, BY DOPAMINERGIC, BY R